3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
56
Genitourinary
6
Thoracic
5
Head & Neck
5
Gynecologic
5
Tumor-Agnostic
4
Other solid neoplasm
4
Sarcoma
2
Dermatologic
2
CNS
2
Endocrine
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Letrozole
34
Fulvestrant
31
Specimen Handling
29
ribociclib
22
pembrolizumab
22
Paclitaxel
21
Magnetic Resonance Spectroscopy
20
palbociclib
19
Trastuzumab
19
Anastrozole
19
Carboplatin
18
Capecitabine
18
exemestane
17
abemaciclib
16
Biopsy
16
Tamoxifen
15
pertuzumab
14
trastuzumab deruxtecan
12
Cyclophosphamide
10
Taxes
9
Radiotherapy
8
Goserelin
8
Docetaxel
8
giredestrant
7
Standard of Care
7
130-nm albumin-bound paclitaxel
7
inavolisib
6
eribulin
6
elacestrant
6
atezolizumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fluorouracil
×
Breast
×
30 days
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled